GLP-1 Drugs Pick Up Another Win, This Time in Psoriatic Arthritis
DENVER — Adding a GLP-1 agonist to psoriasis medication significantly improved outcomes in patients with psoriatic arthritis (PsA) and overweight or obesity, a phase III randomized trial showed. After 36 weeks, almost a third of patients randomized to ixekizumab (Taltz) and tirzepatide (Zepbound) had at least 50% improvement in psoriatic arthritis status (ACR50) and 10%…
